Intranasal administration of recombinant mouse interleukin-12 increases inflammation and demyelination in chronic experimental autoimmune neuritis in Lewis rats

Απλή σελίδα τεκμηρίου
dc.contributor.authorPelidou, S. H.en
dc.contributor.authorZou, L. P.en
dc.contributor.authorDeretzi, G.en
dc.contributor.authorNennesmo, I.en
dc.contributor.authorWei, L.en
dc.contributor.authorMix, E.en
dc.contributor.authorVan Der Meide, P. H.en
dc.contributor.authorZhu, J.en
dc.date.accessioned2015-11-24T19:09:11Z
dc.date.available2015-11-24T19:09:11Z
dc.identifier.issn0300-9475-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20669
dc.rightsDefault Licence-
dc.subjectAdministration, Intranasalen
dc.subjectAnimalsen
dc.subjectB-Lymphocytes/immunology/pathologyen
dc.subjectCD4-Positive T-Lymphocytes/immunology/pathologyen
dc.subjectCD8-Positive T-Lymphocytes/immunology/pathologyen
dc.subjectHistocompatibility Antigens Class II/metabolismen
dc.subjectImmunizationen
dc.subjectInflammation/etiologyen
dc.subjectInterferon-gamma/biosynthesisen
dc.subjectInterleukin-12/*administration & dosage/antagonists & inhibitors/physiologyen
dc.subjectLymphocyte Activationen
dc.subjectMaleen
dc.subjectMiceen
dc.subjectMyelin P0 Protein/immunologyen
dc.subjectNeuritis, Autoimmune, Experimental/*etiology/pathology/therapyen
dc.subjectPolyradiculoneuropathy/etiologyen
dc.subjectRatsen
dc.subjectRats, Inbred Lewen
dc.subjectRecombinant Proteins/administration & dosageen
dc.subjectSciatic Nerve/immunology/pathologyen
dc.titleIntranasal administration of recombinant mouse interleukin-12 increases inflammation and demyelination in chronic experimental autoimmune neuritis in Lewis ratsen
heal.abstractTo examine whether interleukin (IL)-12 modulates ongoing chronic experimental autoimmune neuritis (EAN), we evaluated the effects of recombinant mouse IL-12 (rmIL-12) in Lewis rats with chronic EAN, induced by immunization with P0 peptide (180-199) plus complete Freund's adjuvant. Rats were treated intranasally with either 0.1 or 1 microg/rat/day rmIL-12 for 6 days from the onset of clinical chronic EAN, on days 5-10 postimmunization (p.i.). Only high-dose rmIL-12 exacerbated chronic EAN. This clinical effect was associated with higher numbers of inflammatory cells and more severe demyelination in sciatic nerve sections on days 15 and 80 p.i. compared with low-dose rmIL-12-treated rats and phosphate-buffered saline (PBS)-treated control rats. High-dose rmIL-12 increased significantly the lymph node mononuclear cell proliferation in response to P0 peptide 180-199 and IFN-gamma production in the sciatic nerves. These data indicate that intranasally administered IL-12 acts as a proinflammatory cytokine in chronic EAN. Effective inhibition of IL-12 in vivo could be considered for therapeutic use in chronic inflammatory demyelinating polyradiculoneuropathy.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10632973-
heal.journalNameScand J Immunolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2000-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ